[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0015567A - Compostos de ácido fenoxicarboxìlico e composições para liberar agentes ativos - Google Patents

Compostos de ácido fenoxicarboxìlico e composições para liberar agentes ativos

Info

Publication number
BR0015567A
BR0015567A BR0015567-5A BR0015567A BR0015567A BR 0015567 A BR0015567 A BR 0015567A BR 0015567 A BR0015567 A BR 0015567A BR 0015567 A BR0015567 A BR 0015567A
Authority
BR
Brazil
Prior art keywords
compositions
active agents
acid compounds
releasing active
phenoxycarboxylic acid
Prior art date
Application number
BR0015567-5A
Other languages
English (en)
Other versions
BRPI0015567B1 (pt
BRPI0015567B8 (pt
Inventor
Andrea Leone-Bay
Pinwah Tang
Jun Liao
Kelly Kraft
Destardi Moye-Sherman
John E Smart
David Gschneidner
John J Freeman Jr
Maria A P Boyd
Puchun Liu
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of BR0015567A publication Critical patent/BR0015567A/pt
Publication of BRPI0015567B1 publication Critical patent/BRPI0015567B1/pt
Publication of BRPI0015567B8 publication Critical patent/BRPI0015567B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/92—Unsaturated compounds containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSTOS DE áCIDO FENOXICARBOXìLICO E COMPOSIçõES PARA LIBERAR AGENTES ATIVOS". Provêm-se compostos de ácido fenoxicarboxílico e composições para a liberação de agentes ativos. Provêm-se também métodos de administração e preparação.
BRPI0015567A 1999-11-05 2000-11-06 composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica BRPI0015567B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16380699P 1999-11-05 1999-11-05
US23183600P 2000-09-06 2000-09-06
US23723300P 2000-10-02 2000-10-02
PCT/US2000/030662 WO2001032596A1 (en) 1999-11-05 2000-11-06 Phenoxy carboxylic acid compounds and compositions for delivering active agents

Publications (3)

Publication Number Publication Date
BR0015567A true BR0015567A (pt) 2002-07-16
BRPI0015567B1 BRPI0015567B1 (pt) 2016-10-25
BRPI0015567B8 BRPI0015567B8 (pt) 2021-05-25

Family

ID=27388931

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0015567A BRPI0015567B8 (pt) 1999-11-05 2000-11-06 composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica

Country Status (17)

Country Link
EP (2) EP1226109A4 (pt)
JP (2) JP2004501057A (pt)
KR (1) KR100788970B1 (pt)
CN (1) CN1384814B (pt)
AT (1) ATE427925T1 (pt)
AU (3) AU2622301A (pt)
BR (1) BRPI0015567B8 (pt)
CA (2) CA2388240C (pt)
CZ (2) CZ20021554A3 (pt)
DE (1) DE60041976D1 (pt)
HK (1) HK1048801B (pt)
HU (1) HU229415B1 (pt)
IL (4) IL149337A0 (pt)
MX (2) MXPA02004092A (pt)
NZ (1) NZ530450A (pt)
PL (1) PL201505B1 (pt)
WO (2) WO2001032596A1 (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344213B1 (en) 1996-03-29 2002-02-05 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6916489B2 (en) 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
US6610329B2 (en) 1993-04-22 2003-08-26 Emisphere Technologies Inc. Compositions for the delivery of antigens
CZ302280B6 (cs) 1998-08-07 2011-01-26 Emisphere Technologies, Inc. Slouceniny a prostredky pro dodávání aktivních látek
US6991798B1 (en) 1998-08-07 2006-01-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US7151191B2 (en) 2000-01-13 2006-12-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CZ303736B6 (cs) 2000-06-29 2013-04-17 Emisphere Technologies, Inc. Slouceniny a prostredky pro zavádení aktivních cinidel
US7227033B2 (en) 2002-01-09 2007-06-05 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate
DE60138468D1 (de) * 2000-09-06 2009-06-04 Emisphere Tech Inc Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
RU2309945C2 (ru) 2001-03-01 2007-11-10 Эмисфере Текнолоджиз, Инк. Композиции для доставки бисфосфонатов
ES2400683T3 (es) * 2001-09-26 2013-04-11 Emisphere Technologies, Inc. Método de preparación de ácidos fenoi-alcanoicos y sales de los mismos mediante un producto intermedio de dicarboxilato
ES2431630T3 (es) * 2001-11-13 2013-11-27 Emisphere Technologies, Inc. Compuestos de fenoxiamina y composiciones para administrar principios activos
CA2466863A1 (en) 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
CA2473340C (en) 2002-02-20 2014-12-09 Eli Lilly And Company Formulations comprising a glp-1 compound and a delivery agent, and uses thereof
BRPI0411165A (pt) * 2003-05-14 2006-07-11 Emisphere Tech Inc composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
EP1658285B1 (en) 2003-08-20 2007-05-02 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
WO2005019184A1 (en) 2003-08-20 2005-03-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
JP2007532684A (ja) 2004-04-16 2007-11-15 エミスフェアー・テクノロジーズ・インク 活性剤の送達のための８−（２−ヒドロキシフェノキシ）オクチルジエタノールアミン及びその塩
JP2007536268A (ja) 2004-05-06 2007-12-13 エミスフェアー・テクノロジーズ・インク 固体剤形の湿性ヘパリン
NZ551196A (en) 2004-05-14 2010-08-27 Emisphere Tech Inc Compounds and compositions for delivering active agents
RU2403237C2 (ru) * 2004-05-14 2010-11-10 Эмисфире Текнолоджис, Инк. Составы и смеси для доставки активных агентов
CA2566161C (en) 2004-05-14 2013-10-01 Emisphere Technologies, Inc. Aryl ketone compounds and compositions for delivering active agents
AU2005244986B2 (en) * 2004-05-19 2011-01-27 Emisphere Technologies, Inc. Topical cromolyn formulations
JP5122954B2 (ja) 2004-05-19 2013-01-16 エミスフェアー・テクノロジーズ・インク アシクロビル製剤
BRPI0513101A (pt) * 2004-07-12 2008-04-29 Emisphere Tech Inc forma unitária de dosagem para administração bucal, uso da forma unitária de dosagem e método para preparar a forma unitária de dosagem
JP2008509145A (ja) 2004-08-03 2008-03-27 エミスフィアー テクノロジーズ インコーポレイテッド 抗糖尿病性経口インスリン−ビグアニドの組み合わせ
JP2008509933A (ja) * 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
EP1830831B1 (en) 2004-12-29 2015-01-21 Emisphere Technologies, Inc. Pharmaceutical formulations of gallium salts
US8110547B2 (en) 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
FR2880887B1 (fr) * 2005-01-14 2009-01-30 Merck Sante Soc Par Actions Si Derives d'hydroxyphenols, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
US8975227B2 (en) 2005-07-15 2015-03-10 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
WO2007121471A2 (en) 2006-04-18 2007-10-25 Emisphere Technologies, Inc. Dialkyl ether delivery agents
US8771712B2 (en) 2006-05-09 2014-07-08 Emisphere Technologies, Inc. Topical administration of acyclovir
JP5475443B2 (ja) 2006-06-28 2014-04-16 エミスフェアー・テクノロジーズ・インク 硝酸ガリウム製剤
US20100062970A1 (en) 2006-08-18 2010-03-11 Emisphere Technologies Inc. Synthesis of propyl phenoxy ethers and use as delivery agents
WO2008027958A2 (en) * 2006-08-31 2008-03-06 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP5544169B2 (ja) * 2007-02-08 2014-07-09 エミスフェアー・テクノロジーズ・インク フェニルアルキルカルボン酸誘導体送達剤
EP3050568B1 (en) 2007-03-13 2020-12-02 JDS Therapeutics, LLC Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
EP2461803B1 (en) 2009-08-03 2018-10-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
EP2531202A4 (en) * 2010-02-04 2013-07-17 Lowell C Parsons USE OF HEPARIN-BASED ORAL PREPARATIONS FOR TREATING DISEASES AND DISEASES OF THE URINARY TRACT
JP6152346B2 (ja) 2011-03-01 2017-06-21 ジェーディーエス セラピューティックス、エルエルシーＪＤＳ Ｔｈｅｒａｐｅｕｔｉｃｓ，ＬＬＣ 糖尿病、低血糖、および関連障害の治療および予防のためのインスリンとクロムの組成物
CN104135859B (zh) 2011-12-28 2017-06-27 全球血液疗法公司 取代的苯甲醛化合物及其用于增加组织氧合的方法
IN2014MN01484A (pt) * 2011-12-28 2015-05-01 Artur Viktorovich Martynov
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
ES2657601T3 (es) 2012-08-23 2018-03-06 Emisphere Technologies, Inc. Compuestos de fenoxi alquil dietanolamina y diisopropanolamina para la administración de agentes activos
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
CA2903220C (en) 2013-03-15 2023-01-24 Qing Xu Aldehyde compounds and uses thereof for the modulation of hemoglobin
KR101971385B1 (ko) 2013-03-15 2019-04-22 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
KR102588476B1 (ko) 2014-02-07 2023-10-11 글로벌 블러드 테라퓨틱스, 인크. 2-하이드록시-6-((2-(1-이소프로필-1h-피라졸-5-일)피리딘-3-일)메톡시)벤즈알데하이드의 유리 염기의 결정성 다형체
US20180050096A1 (en) 2015-02-09 2018-02-22 Entera Bio Ltd. Treatment of hypoparathyroidism
SG10201912511WA (en) 2015-12-04 2020-02-27 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CA3014308A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
CN116850132A (zh) 2016-08-17 2023-10-10 安提拉生物有限公司 用于口服的活性剂的制剂
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2375138A (en) 1942-05-01 1945-05-01 American Cyanamid Co Alkamine esters of aryloxymethyl benzoic acid
NL133069C (pt) * 1966-07-29
JPS55145648A (en) * 1979-05-02 1980-11-13 Hisamitsu Pharmaceut Co Inc New derivative of anthranylic acid
ZM5780A1 (en) * 1979-06-29 1983-11-21 Wellcome Found Pharmaceutical ethers,preparation,use and intermediates therefor and their preparation
JPS5750946A (en) * 1980-09-10 1982-03-25 Hisamitsu Pharmaceut Co Inc Novel anthranilic acid derivative
DE3206030A1 (de) * 1981-02-19 1982-09-09 Fuji Photo Film Co., Ltd., Minami-Ashigara, Kanagawa Verfahren zur bildung von polymeren bildern und druckplatten
IE54269B1 (en) * 1981-12-30 1989-08-02 Ici America Inc Pharmaceutically active phenylcarboxylic acid derivatives
JPS58142901A (ja) * 1982-02-19 1983-08-25 Nippon Zeon Co Ltd ゴムの変性方法
JPH0245481A (ja) * 1988-08-03 1990-02-15 Yamamura Kagaku Kenkyusho:Kk クマラン化合物の製造法
DE4142514A1 (de) * 1991-12-21 1993-06-24 Basf Ag Verfahren zur bekaempfung von pilzen
FR2687316B3 (fr) * 1992-02-13 1994-08-12 Rolland Sa A Nouvelle utilisation de compositions pharmaceutiques a base de derives phenoxyacetiques en vue de la restauration des fonctions nerveuses.
IL104283A (en) * 1992-12-30 1996-12-05 Agis Ind 1983 Ltd Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate
US5364767A (en) * 1993-02-11 1994-11-15 Research Organics, In. Chromogenic compounds and methods of using same
FR2710782A1 (fr) * 1993-09-29 1995-04-07 Sodern Tube neutronique à confinement magnétique des électrons par aimants permanents et son procédé de fabrication.
US5837702A (en) * 1993-10-07 1998-11-17 Bristol-Myers Squibb Co. 4-arylamino-benzopyran and related compounds
TW270114B (pt) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5783593A (en) * 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5747537A (en) * 1995-09-05 1998-05-05 Washington University Method of inhibiting parasitic activity
JPH09207543A (ja) * 1996-02-08 1997-08-12 Denso Corp 空調装置
EP0969869A2 (en) * 1996-07-26 2000-01-12 Susan P. Perrine Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders
WO1998018610A1 (en) * 1996-10-28 1998-05-07 Lengerich Bernhard H Van Embedding and encapsulation of controlled release particles
WO1999036060A1 (en) * 1998-01-20 1999-07-22 Applied Analytical Industries, Inc. Oral liquid compositions

Also Published As

Publication number Publication date
HU229415B1 (en) 2013-12-30
MXPA02004092A (es) 2003-02-12
EP1226104A1 (en) 2002-07-31
HK1048801B (en) 2009-08-28
ATE427925T1 (de) 2009-04-15
IL149337A0 (en) 2002-11-10
DE60041976D1 (de) 2009-05-20
IL149336A0 (en) 2002-11-10
CZ20021570A3 (cs) 2002-10-16
CN1384814A (zh) 2002-12-11
CA2390025A1 (en) 2001-05-10
HUP0600033A2 (en) 2006-08-28
MXPA02004451A (es) 2002-10-23
HK1048801A1 (en) 2003-04-17
AU1655401A (en) 2001-05-14
WO2001032130A2 (en) 2001-05-10
CZ20021554A3 (cs) 2002-10-16
CN1384814B (zh) 2015-11-25
BRPI0015567B1 (pt) 2016-10-25
JP5117658B2 (ja) 2013-01-16
JP2003513060A (ja) 2003-04-08
KR100788970B1 (ko) 2007-12-27
EP1226104A4 (en) 2005-05-04
AU2622301A (en) 2001-05-14
KR20020060222A (ko) 2002-07-16
CA2388240C (en) 2010-04-20
IL195055A0 (en) 2009-08-03
AU2005248960A1 (en) 2006-02-02
NZ530450A (en) 2004-06-25
IL195055A (en) 2015-07-30
AU2005248960B2 (en) 2009-01-29
EP1226104B1 (en) 2009-04-08
CA2388240A1 (en) 2001-05-10
WO2001032130A3 (en) 2002-03-14
PL354996A1 (en) 2004-03-22
JP2004501057A (ja) 2004-01-15
WO2001032596A1 (en) 2001-05-10
WO2001032596A8 (en) 2001-08-09
BRPI0015567B8 (pt) 2021-05-25
PL201505B1 (pl) 2009-04-30
AU783157B2 (en) 2005-09-29
EP1226109A2 (en) 2002-07-31
EP1226109A4 (en) 2005-01-26
IL149337A (en) 2010-04-15

Similar Documents

Publication Publication Date Title
BR0015567A (pt) Compostos de ácido fenoxicarboxìlico e composições para liberar agentes ativos
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
TR200200561T2 (tr) Mesalazin içeren ve vücut içinde kontrollü bir şekilde salgılanabilen ağızdan alınan farmasötik bileşimler
AU3357800A (en) Method of preparing alkylated salicylamides
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
BR0214199A (pt) Composições de fenóxi amina para liberar agentes ativos, forma de unidade de dosagem e método de administração
IL140710A0 (en) Pulmonary delivery of active agents
UY27320A1 (es) Nuevas composiciones farmacéuticas
RS50046B (sr) Farmaceutske kompozicije tizoksanida i nitazoksanida
WO2002015959A3 (en) Compounds and compositions for delivering active agents
MY129437A (en) Drug formulation having controlled release of active compound
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
ITMI930582A1 (it) Composizione farmeceutiche ad attivita' analgesica
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.
CA2394471A1 (en) External preparation for treating pruritus
EP1027051A4 (en) ANTITHROMBOTIC AGENTS
SE9902742D0 (sv) New pharmaceutical formultion
ATE268768T1 (de) Antithrombosemittel
CU23150A3 (es) Formulacion de medicamento con liberacion controlada de sustancia activa
ECSP941154A (es) Procedimiento para preparar una composicion farmaceutica a base de ciclosporina
ITMI992220A0 (it) Composizioni per la somministrazione topica di ingredienti attivi cosm etici

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: ATRAVES DA PETICAO NO 020924, ( 06/11/2003), O REQUERENTE SOLICITOU O EXAME DO PRESENTE E EFETUOU A RETRIBUICAO EQUIVALENTE A 21 REIVINDICACOES. NO ENTANTO, EM PETICAO NO 018080049932 ( 07/08/2008 ) FOI APRESENTADO UM NOVO QUADRO REIVINDICATORIO CONSTANDO 22 REIVINDICACOES. DESSE MODO, A FIM DE DAR CONTINUIDADE AO EXAME DO PEDIDO O REQUERENTE DEVERA COMPLEMENTAR A RETRIBUICAO EQUIVALENTE A 1 REIVINDICACAO EXCEDENTE.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REFERENTE A RPI 2028 DE 17/11/2009.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/10/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/11/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 06/11/2020